Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection

  • 384 Accesses

  • 19 Citations


The purpose of this study was to evaluate the prevalence and clinical risk factors for quinolone resistance (QR) in E. coli strains from males with febrile urinary tract infection (FUTI). An ambispective cross-sectional study was performed in which we evaluated 153 males with a community FUTI caused by E. coli. Among the 153 FUTI episodes, 101 (66%) were due to quinolone susceptible E. coli strains while 52 (34%) were caused by QR E. coli strains. In the univariate analysis QR was associated with older age, higher Charlson scores, dementia, past UTI, urinary tract abnormalities, previous antibiotic use, particularly with fluoroquinolones (FQ), a healthcare-associated (HA)-UTI (HA-UTI) and to four of the components included in the definition of HA-UTI: hospital admission, nursing home residence, indwelling urethral catheter and invasive urinary instrumentation. In the multivariate analysis, HA-UTI (OR 3.82, 95% CI 1.3–11.24; P 0.015) and use of antimicrobials in the previous month (OR 5.82, 95% CI 2.3–14.88; P < 0.001) mainly with FQ (OR 13.97, 95% CI 2.73–71.53; P 0.002) were associated with QR. To have a HA-UTI and a previous use of FQ in the preceding month were strong risk factors for QR E. coli, and thus empirical antimicrobial treatment with quinolones should be avoided in these patients.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.


  1. 1.

    Ulleryd P (2003) Febrile urinary tract infection in men. Int J Antimicrob Agents 22(Suppl 2):89–93

  2. 2.

    Horcajada JP, Vilana R, Moreno-Martínez A, Alvarez-Vijande R, Bru C, Bargallo X, Buñesch L, Martinez JA, Mensa J (2003) Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications. Scand J Infect Dis 35:114–120

  3. 3.

    Velasco M, Mateos JJ, Martínez JA, Moreno-Martinez A, Horcajada JP, Barranco M, Lomeña F, Mensa J (2004) Accurate topographical diagnosis of urinary tract infection in male patients with (111) indium-labelled leukocyte scintigraphy. Eur J Intern Med 15:157–161

  4. 4.

    Krieger JN, Nyberg L, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282:236–237

  5. 5.

    Naber KG, Sörgel F (2003) Antibiotic therapy: rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and prostatic tissue. Andrologia 35:331–335

  6. 6.

    Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, Rozwadowski J, Mehler PS, Price CS (2008) Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 121:876–884

  7. 7.

    European Centre for Disease Prevention and Control (2010) Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)2009. Available at: Accessed 6 January 2011

  8. 8.

    Killgore KM, March KL, Guglielmo BJ (2004) Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 38:1148–1152

  9. 9.

    Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group (2005) Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 56:914–918

  10. 10.

    Colodner R, Kometiani I, Chazan B, Raz R (2008) Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 36:41–45

  11. 11.

    Lautenbach E, Fishman NO, Bilker WB, Castiglioni A, Metlay JP, Edelstein PH, Strom BL (2002) Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 162:2469–2477

  12. 12.

    Etienne M, Chavanet P, Sibert L, Michel F, Levesque H, Lorcerie B, Doucet J, Pfitzenmeyer P, Caron F (2008) Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 30:8–12

  13. 13.

    Khawcharoenporn T, Vasoo S, Ward E, Singh K (2010) High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med. doi:10.1016/j.ajem.2010.09.030, Epub ahead of print

  14. 14.

    Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–797

  15. 15.

    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method for classifying comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

  16. 16.

    Lipsky BA, Ireton RC, Fihn SD, Hackett R, Berger RE (1987) Diagnosis of bacteriuria in men: specimen collection and culture interpretation. J Infect Dis 155:847–854

  17. 17.

    CLSI (2007) Performance Standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100S17. Clinical and Laboratory Standard Institute, Wayne, PA

  18. 18.

    Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A (2008) Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168:1897–1902

  19. 19.

    Velasco M, Horcajada JP, Mensa J, Mensa J, Moreno-Martinez A, Vila J, Martinez JA, Ruiz J, Barranco M, Roig G, Soriano E (2001) Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis 33:1682–1686

  20. 20.

    Alos JI, Serrano MG, Gomez-Garces JL, Perianes J (2005) Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 11:199–203

  21. 21.

    Koeijers JJ, Verbon A, Kessels AG, Bartelds A, Donkers G, Nys S, Stobberingh EE (2010) Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility. Urology 76:336–340

  22. 22.

    Lautenbach E, Metlay JP, Mao X, Han X, Fishman NO, Bilker WB, Tolomeo P, Wheeler M, Nachamkin I (2010) The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis 51:280–285

  23. 23.

    Hawkey PM (2003) Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 51(Suppl 1):29–35

  24. 24.

    Tavio MM, Vila J, Ruiz J, Martin-Sanchez AM, Jimenez de Anta MT (1999) Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli. J Antimicrob Chemother 44:735–742

  25. 25.

    Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 44:2233–2241

  26. 26.

    Poirel L, Cattoir V, Nordmann P (2008) Is plasmid-mediated quinolone resistance a clinically significant problem? Clin Microbiol Infect 14:295–297

  27. 27.

    Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD (2010) Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 340:c2096. doi:10.1136/bmj.c2096

  28. 28.

    Horcajada JP, Vila J, Moreno-Martínez A, Ruiz J, Martínez JA, Sánchez M, Soriano E, Mensa J (2002) Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother 49:55–59

  29. 29.

    Johnson JR, Scheutz F, Ulleryd P, Kuskowski MA, O’Bryan TT, Sandberg T (2005) Phylogenetic and pathotypic comparison of concurrent urine and rectal Escherichia coli isolates from men with febrile urinary tract infection. J Clin Microbiol 43:3895–3900

  30. 30.

    Mazzoli S (2010) Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunol Med Microbiol 59:337–344

  31. 31.

    Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A (2005) Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 5:37

  32. 32.

    Ruiz J, Gomez J, Navia MM, Ribera A, Sierra JM, Marco F, Mensa J, Vila J (2002) High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis 42:257–261

  33. 33.

    Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H, Çek M, Lobel B, Naber KG, Palou J, Tenke P, Wagenlehner F (2009) Guidelines on urological infections. European Association of Urology 2009. Available at Accessed February 2011

Download references

Conflicts of interest

None to declare.

Author information

Correspondence to A. Smithson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Smithson, A., Chico, C., Ramos, J. et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 31, 423–430 (2012) doi:10.1007/s10096-011-1322-y

Download citation


  • Urinary Tract Infection
  • Coli Strain
  • Quinolone Resistance
  • Clinical Laboratory Standard Institute
  • Febrile Urinary Tract Infection